A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non–small cell lung cancer
Hirva Mamdani(Wayne State University), Jeffrey Clarke(Duke Medical Center), Lin Gu(Tsinghua University), Ryan D. Gentzler(University of Virginia Health System), Edward F. Patz(G1 Therapeutics (United States)), Sarada Gurubhagavatula(Harvard University), Greg Andrew Durm(Indiana University Health), Alberto Chiappori(Moffitt Cancer Center), James E. Herndon(Duke University), Frank Weinberg(University of Illinois Chicago), Thomas E. Stinchcombe(Duke Medical Center)
Cited by 3
Related Papers
Exploring atomic defects in molybdenum disulphide monolayers
|Nature Communications|2015|1.5k
Matching the kinetics of natural enzymes with a single-atom iron nanozyme
|Nature Catalysis|2021|1.1k
Ultrahigh–energy density lead-free dielectric films via polymorphic nanodomain design
|Science|2019|1.1k
Direct observation of noble metal nanoparticles transforming to thermally stable single atoms
|Nature Nanotechnology|2018|1.1k